Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Johnson & Johnson is a diversified healthcare conglomerate operating across pharmaceuticals (60%+ of revenue), medical devices (cardiovascular, orthopedics, surgery), and consumer health products. Following the 2023 Kenvue spin-off, JNJ is now a pure-play pharmaceutical and MedTech company with blockbuster drugs like Stelara, Darzalex, and Tremfya, plus leading positions in surgical robotics and electrophysiology. The company generates exceptional margins (72.8% gross, 27.2% operating) through patent-protected drugs and premium medical devices sold globally.
JNJ monetizes through two high-margin models: (1) Patent-protected pharmaceuticals with pricing power in specialty therapeutic areas, generating 70%+ gross margins through R&D-driven innovation and regulatory exclusivity periods of 10-15 years post-approval. Key drugs command premium pricing due to clinical efficacy in hard-to-treat conditions. (2) Medical devices sold to hospitals and surgical centers with recurring revenue from consumables (sutures, surgical staplers) and capital equipment (robotic surgery platforms, electrophysiology mapping systems). Device business benefits from hospital capital spending cycles and procedural volume growth. Geographic diversification across US (50%+ of sales), Europe (25%), and emerging markets provides revenue stability.
Pharmaceutical pipeline readouts and FDA approvals - particularly in immunology, oncology, and pulmonary hypertension where JNJ has late-stage assets
Loss of exclusivity (LOE) events and biosimilar competition - Stelara biosimilars launched in 2025, Remicade already facing competition
MedTech procedural volume recovery - elective surgeries, orthopedic procedures, and cardiovascular interventions drive device sales
Legal settlements and litigation outcomes - talc liabilities, opioid settlements, and product liability cases create headline risk
M&A activity and capital deployment - bolt-on acquisitions in high-growth therapeutic areas, share buybacks with $19.7B annual FCF
Patent cliffs and biosimilar erosion - Stelara (psoriasis/Crohn's, $10B+ annual sales) faces US biosimilar competition starting 2025, Remicade already genericized. Pipeline must replace $15B+ in LOE revenue over next 5 years
Drug pricing pressure and regulatory reform - IRA Medicare negotiation provisions, international reference pricing, and potential legislation limiting price increases threaten pharmaceutical margins
GLP-1 competitive threat to metabolic franchises - Novo Nordisk and Eli Lilly's weight loss drugs may reduce demand for cardiovascular and diabetes-adjacent therapies
Pharmaceutical R&D productivity - competitors (Pfizer, Merck, AbbVie) advancing in immunology and oncology with potentially superior mechanisms. JNJ must maintain 2-3 major drug approvals annually to sustain growth
MedTech innovation cycle - Intuitive Surgical dominates robotic surgery, Medtronic and Abbott lead in cardiovascular devices. JNJ's Ottava surgical robot delayed, risking share loss in high-growth segments
Talc litigation liabilities - $8.9B proposed bankruptcy settlement for ovarian cancer claims remains unresolved, with potential for additional claims and higher settlement costs
Pension and post-retirement obligations - underfunded status creates long-term cash drag, though manageable given FCF profile
low - Pharmaceutical demand is non-discretionary and driven by disease prevalence rather than GDP growth. MedTech segment shows moderate cyclicality tied to hospital capital budgets and elective procedure volumes, which can defer during recessions, but emergency and critical care procedures remain stable. Overall revenue resilience during downturns due to 60% pharma weighting and essential healthcare nature.
Rising rates have modest negative impact through two channels: (1) Higher discount rates compress valuation multiples for long-duration pharma cash flows, as drug patents create predictable 10-15 year revenue streams that get discounted more heavily. (2) Moderate debt load ($35B) sees incrementally higher refinancing costs, though 0.59 D/E ratio is manageable. Partially offset by higher returns on $24.5B operating cash flow invested in short-term instruments. Overall sensitivity is low given strong FCF generation and investment-grade balance sheet.
Minimal direct exposure. Healthcare demand is not credit-dependent. Hospital customers have stable payment profiles. Company maintains investment-grade rating (AAA/Aa1) with strong interest coverage. Legal settlement financing represents only credit-related risk, but $19.7B annual FCF provides ample coverage.
value and dividend - JNJ attracts defensive investors seeking stable cash flows, 3.0% dividend yield with 62-year consecutive increase history, and recession-resistant earnings. Recent 54.8% one-year return reflects re-rating from litigation overhang resolution and strong pipeline execution. Lower beta (0.5-0.6) appeals to risk-averse institutional investors and retirees. Growth component emerging from newer immunology and oncology franchises attracting GARP investors.
low - Beta typically 0.5-0.6 reflecting defensive healthcare characteristics. Stock exhibits lower volatility than S&P 500 due to diversified revenue base, non-cyclical demand, and predictable cash flows. Volatility spikes occur around litigation headlines, FDA decisions, and major pipeline readouts, but baseline volatility remains subdued.
